Evidence mapPaperPMID 42539404Full record

ArticleFrontiers in immunology2026

Superior inflammatory response and MASH progression in

Anja R Geisler, Nora Meinhardt, Laura Otto, Yvonne Hupfer, Betty Hebecker, Bill J Perkowski, Markus Werner, Wan-Ting Zhao, Karl-Heinz Herrmann, Marcus Ebert and 7 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anja R Geisler *Institute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Nora Meinhardt *Institute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Laura OttoInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Yvonne HupferInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Betty HebeckerInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Bill J PerkowskiInstitute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.
Markus WernerInstitute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.
Wan-Ting ZhaoMedical Physics Group, Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Karl-Heinz HerrmannMedical Physics Group, Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Marcus EbertMVZ Medical Laboratories Dessau Kassel GmbH, Dessau, Germany.
Sandra BurghoffMVZ Medical Laboratories Dessau Kassel GmbH, Dessau, Germany.
Jürgen R ReichenbachMedical Physics Group, Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Norbert GerdesDepartment of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Oliver WerzInstitute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.
Anna P KippInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Stefan LorkowskiInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.
Maria Witt-WallertInstitute of Nutritional Science, Friedrich Schiller University Jena, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic dysfunction-associated steatohepatitis (MASH) represents a critical progression of metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by hepatic steatosis, inflammation, and beginning fibrosis. The selection of appropriate animal models is crucial for understanding disease mechanisms and evaluating therapeutic interventions. While wild-type C57BL/6 mice are widely used, hyperlipidemic apolipoprotein E-deficient ( Methods: Male wild-type C57BL/6J and male Results: Conclusion:

Indexed as

Apolipoproteins EInflammationNon-alcoholic Fatty Liver DiseaseAnimalsCytokinesDiet, High-FatDisease Models, AnimalDisease ProgressionLiverMaleMiceMice, Inbred C57BLMice, KnockoutApolipoproteins ECytokinesAPOEinflammationMASLDmetabolic dysfunctionNAFLD

Identifiers

PMID42539404
PMCPMC13423675

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.